Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
Sponsor: Peking University Cancer Hospital & Institute
Summary
It is a prospective, multicenter, randomized controlled trial to investigate the predictive value of MRD on adjuvant therapy. Stage IA2-II resected NSCLC patients will undergo two-round MRD tests after surgery, first in 3-7 days and second in 1 month after surgery. And patients who confirm two-round landmark undetectable MRD will be enrolled and randomly assigned to the conventional treatment group or the adaptive therapy group . Patients in the the adaptive therapy group will undergo closely MRD and imaging monitoring without adjuvant therapy if the MRD was negative.
Official title: A Prospective Multicenter Randomized Controlled Study of Adaptive Therapy in Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
286
Start Date
2025-04-06
Completion Date
2029-12-31
Last Updated
2025-10-02
Healthy Volunteers
No
Conditions
Interventions
Standard Therapy
For patients with negative EGFR/ALK mutation, adjuvant chemotherapy or adjuvant chemotherapy combined with immunotherapy was administered, for patients with positive EGFR/ALK mutation, targeted therapy was administered.
Adaptive Therapy
Patients will be under close MRD and imaging monitoring without adjuvant therapy if the MRD was negative.
Locations (1)
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China